Alzex Neuropharma Inc TRRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.14
- Day Range
- $0.15–0.15
- 52-Week Range
- $0.10–0.50
- Bid/Ask
- $0.13 / $0.28
- Market Cap
- $225,790.20
- Volume/Avg
- 174 / 1,482
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alzex Neuropharma Inc is a development-stage biopharmaceutical company that has developed and patented precision therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquees) a French academic engineering and research institute.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.trinresinc.com
Valuation
|
Metric
|
TRRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TRRI
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | — |
Quick Ratio
No chart available
Profitability
|
Metric
|
TRRI
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wghrczrcnf | Nvfc | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Snqystnz | Qvbkszc | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kcqwzvws | Ywxgtd | $99.6 Bil | |
MRNA
| Moderna Inc | Szflbpy | Dqjf | $38.8 Bil | |
ARGX
| argenx SE ADR | Bqyjrfbg | Rhfg | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Tqgghyrk | Rqsyw | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vybxfxn | Vchhp | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qsqhxntm | Dpvmybw | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ygswyrrpkd | Fyffyw | $12.4 Bil | |
INCY
| Incyte Corp | Dyjdrkz | Yyrgg | $11.9 Bil |